📊 GLSI Key Takeaways
Is Greenwich LifeSciences, Inc. (GLSI) a Good Investment?
Greenwich LifeSciences is a pre-revenue pharmaceutical development-stage company burning 4.7M annually in operating cash flow with no commercial revenue. While the balance sheet is fortress-like with 10.5M cash and zero debt, the company's 2+ year runway masks a fundamental problem: complete absence of revenue, negative profitability, and an unproven pipeline with execution risk that cannot be assessed from financial data alone.
GLSI is a pre‑revenue biotech with sustained operating losses and an extremely small asset base, leaving it dependent on external financing. Cash of $3.81M against a trailing operating cash outflow of $6.74M implies a short runway and high dilution risk. While liabilities are low and there is no debt, fundamentals point to near‑term capital needs without offsetting revenue or profitability visibility.
Greenwich LifeSciences, Inc. Key Strengths (GLSI)
- Pristine balance sheet with zero debt and no long-term liabilities
- Strong liquidity position with 10.5M in cash and 2.01x current ratio
- Sufficient cash runway of approximately 2+ years at current burn rate to pursue clinical development
- Debt-free capital structure
- High current and quick ratios
- Simple, cash-heavy balance sheet
GLSI Stock Risks: Greenwich LifeSciences, Inc. Investment Risks
- No revenue generation with pre-revenue business model creating structural unprofitability
- Negative operating cash flow of -4.7M annually indicating unsustainable cash burn
- Pharmaceutical pipeline risk: entire enterprise value depends on clinical trial success and regulatory approval with no visibility into stage of development or probability of success
- Short cash runway vs. burn implies dilution
- No revenue and persistent operating losses
- Going concern and clinical/regulatory execution risk
Key Metrics to Watch
- Cash balance decline rate and remaining runway months
- Operating cash flow trend and path to positive cash flow
- Clinical development milestones and regulatory filings that validate pipeline viability
- Cash runway (months)
- Shares outstanding/dilution rate
Greenwich LifeSciences, Inc. (GLSI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.01x current ratio provides a solid financial cushion.
GLSI Profit Margin, ROE & Profitability Analysis
GLSI vs Healthcare Sector: How Greenwich LifeSciences, Inc. Compares
How Greenwich LifeSciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Greenwich LifeSciences, Inc. Stock Overvalued? GLSI Valuation Analysis 2026
Based on fundamental analysis, Greenwich LifeSciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Greenwich LifeSciences, Inc. Balance Sheet: GLSI Debt, Cash & Liquidity
GLSI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Greenwich LifeSciences, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.34 indicates the company is currently unprofitable.
GLSI Revenue Growth, EPS Growth & YoY Performance
Greenwich LifeSciences, Inc. Dividends, Buybacks & Capital Allocation
GLSI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Greenwich LifeSciences, Inc. (CIK: 0001799788)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GLSI
What is the AI rating for GLSI?
Greenwich LifeSciences, Inc. (GLSI) has a Combined AI Grade of C from Claude (C) and ChatGPT (D) with 57% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GLSI's key strengths?
Claude: Pristine balance sheet with zero debt and no long-term liabilities. Strong liquidity position with 10.5M in cash and 2.01x current ratio. ChatGPT: Debt-free capital structure. High current and quick ratios.
What are the risks of investing in GLSI?
Claude: No revenue generation with pre-revenue business model creating structural unprofitability. Negative operating cash flow of -4.7M annually indicating unsustainable cash burn. ChatGPT: Short cash runway vs. burn implies dilution. No revenue and persistent operating losses.
What is GLSI's revenue and growth?
Greenwich LifeSciences, Inc. reported revenue of N/A.
Does GLSI pay dividends?
Greenwich LifeSciences, Inc. does not currently pay dividends.
Where can I find GLSI SEC filings?
Official SEC filings for Greenwich LifeSciences, Inc. (CIK: 0001799788) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GLSI's EPS?
Greenwich LifeSciences, Inc. has a diluted EPS of $-0.39.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is GLSI's fundamental grade?
Based on our AI fundamental analysis in June 2026, Greenwich LifeSciences, Inc. has a C grade with 57% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is GLSI stock overvalued or undervalued?
Valuation metrics for GLSI: ROE of -107.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is GLSI's AI grade for 2026?
Our dual AI analysis gives Greenwich LifeSciences, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GLSI's free cash flow?
Greenwich LifeSciences, Inc.'s operating cash flow is $-4.7M, with capital expenditures of N/A.
How does GLSI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -107.3% (avg: 15%), current ratio 2.01 (avg: 2).